[211 Pages Report] The global chemotherapy-induced myelosuppression treatment market stands at a net worth of US$ 8.06 Billion in 2022, and is predicted to rise at a CAGR of 3.3% over the forecast period to attain a valuation of US$ 9.78 Billion by 2028.
| Attributes | Details |
|---|---|
| Chemotherapy-Induced Myelosuppression Treatment Market Size (2022) | US$ 8.06 Billion |
| Sales Forecast (2028) | US$ 9.78 Billion |
| Global Market Growth Rate (2022 to 2028) | 4.6% CAGR |
| Share of Top 5 Market Players | 50% |
Chemotherapy-induced myelosuppression treatment accounted for 6.5% share of the global cancer immunotherapy market in 2021.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 3.23% |
| H1, 2022 Projected | 3.26% |
| H1, 2022 Outlook | 3.16% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 07 ↓ |
The market for chemotherapy-induced myelosuppression treatment is subject to changes as per regulatory dynamics and product safety impositions, in lieu of the macro and industry standards.
The comparative analysis and market growth rate of global chemotherapy-induced myelosuppression treatment market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 10 BPS, and, a negative BPS growth is expected in H1-2022 over H1- 2021 duration with 07 Basis Point Share (BPS).
The dip in the BPS values is associated with increased healthcare resource utilization for the treatment of chemotherapy induced myelosuppression, thus incurring high costs associated with treatment. With increasing use of supportive care interventions and associated burden of cost to the patient, the market observed a decline in the BPS values, owed to lower patient preference for the treatment modality.
The key development in the market includes the introduction of COSELA™ (trilaciclib), which is the first approved myeloprotection therapy. With the advent of novel therapies for chemotherapy-induced myelosuppression treatment, the market is expected to observe a positive growth outlook during the forecast period.
“Need for Early Diagnosis & Reduction in Cancer Mortality Driving Market Growth”
During the historical period of 2013 to 2021, the chemotherapy-induced myelosuppression treatment market expanded at a CAGR of 3%.
Chemotherapy-induced myelosuppression is lesser ability of bone marrow to produce blood cells (WBC, RBC, and platelets). This mostly occurs in cancer patients as an adverse effect of chemotherapy drugs, especially in those cases that are located near the bone marrow or larger bones with cavities.
Chemotherapy-induced myelosuppression can result in decreased production of red blood cells (anaemia), white blood cells (leukopenia), and platelets (thrombocytopenia).
Significant research & development activities have resulted from the growing incidence of leukaemia, prompting various pharmaceutical and drug corporations to invest in cancer-related research. The rapidly increasing rate of anaemia and thrombocytopenia among the elderly population base will also benefit industry dynamics.
The growth of the chemotherapy-induced myelosuppression treatment market can be majorly attributed to the increasing availability of comparatively cost-effective biosimilars in the chemotherapy-induced myelosuppression treatment market.
The global chemotherapy-induced myelosuppression treatment solutions market is anticipated to rise at a CAGR of 3.3% from 2022 to 2028.
Principal Consultant
“Extensive Drug Pipeline Likely to Increase Availability of Cost-Effective Products for Chemotherapy-Induced Myelosuppression Treatment”
Growing emphasis on the research and development of drugs and therapies for chemotherapy-induced myelosuppression treatment in conditions such as neutropenia, anaemia and thrombocytopenia, is expected to create significant growth opportunities in the chemotherapy-induced myelosuppression treatment market.
Growing R&D expenditure by pharmaceutical industries for the various drugs used for chemotherapy-induced myelosuppression treatment is expected to boost the product pipeline.
Presence of various clinical-stage pharmaceutical companies, which are focusing on the development of novel drugs for chemotherapy-induced myelosuppression treatment, is expected to be a major forecast impact factor.
Cancer is the second-leading cause of death worldwide. Global availability of advanced treatment options such as chemotherapy, radiotherapy & surgical procedures is also boosting the chemotherapy-induced myelosuppression treatment market.
Early diagnosis of cancer has enhanced the treatment-seeking rate in the developed world, which is, in turn, a major driver of the chemotherapy-induced myelosuppression treatment market.
Chemotherapy-induced myelosuppression treatment holds significant potential for revenue generation in developing countries owing to improving treatment-seeking rates and improving product availability.
“Long Process for Approval of Drugs for Myelosuppression Treatment”
The market is being disrupted by the lengthy approval procedure for medications for myelosuppression treatment. The high cost of medications, as well as other demanding regulatory processes, are posing further challenges to the market growth.
A metallic taste, redness, muscle aches, and arthralgia, as well as the possibility of allergic responses are all common adverse effects of iron therapy. In addition, loss of patent protection and strong competition may impede market expansion.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
“Rising Investments in R&D for Myelosuppressive Therapies Driving Market Growth in North America”
North America is leading the global chemotherapy-induced myelosuppression treatment solutions market. The market will gain traction with significant increase in R&D spending for myelosuppressive therapies and the existence of a well-established healthcare industry.
Rising cancer prevalence, expanded infrastructure, and increased healthcare awareness are some of the reasons driving market expansion in this region. Favorable reimbursement rules, robust commercial operations, and a large patient pool are driving the growth in North America.
“Prominent Presence of Cancer Therapeutics Providers in the U.S.”
The market in the U.S. is likely to expand at a rapid pace over the forecast period. The presence of top cancer therapy providers, large R&D investments, and developed healthcare systems are driving the market growth in the U.S.
Rising cancer burden in the United States has created numerous growth prospects for top cancer therapeutics providers, resulting in increased product demand.
“Rising Penetration of Advanced Cancer Care Treatments”
The China chemotherapy-induced myelosuppression treatment products and services market is speculated to exhibit a high growth owing to numerous initiatives taken by various organizations to enhance awareness, educate the public, and raise finances for chronic diseases.
Industrial growth, rising senior population and cancer prevalence, rising disposable income, and rapid deployment of advanced cancer care treatments are all contributing to the market growth in China.
“Chemotherapy-Induced Myelosuppression Therapies Widely Employed for Treatment of Neutropenia”
Neutropenia indication is expected to account 61.6% share of the chemotherapy-induced myelosuppression treatment market in 2022. The global chemotherapy-induced myelosuppression treatment market is classified into three categories based on the indication: anaemia, neutropenia, and thrombocytopenia.
Neutropenia is a blood disorder characterized by decreased neutrophil counts, which are white blood cells that protect the body from infection. One of the most common side effects of chemotherapy is neutropenia, which can lead to life-threatening infections if left untreated.
“Higher Effectiveness of Erythropoietin Stimulating Agents in Myelosuppression Treatment”
Market share of erythropoietin stimulating agents will grow as the number of instances of anaemia rises, according to pharmacological class. According to the World Health Organization (WHO), anaemia affects more than 1.62 billion people worldwide, accounting for 24.8% of the total population.
These drugs not only reduce transfusion rates but also enhance cognition. They also reduce the need for blood transfusions and are often used by physicians for their cancer patients undergoing chemotherapy to ensure a better quality of life. Erythropoietin stimulating agents are also commonly utilized to boost red blood cell formation in the bone marrow.
The COVID-19 pandemic has had an impact on every industry, including healthcare. Because of the delayed commercial activity across numerous industrial verticals as a result of the COVID-19 crisis, the world economy was severely disrupted. Due to increased hospital admissions and limited healthcare facility visits to combat the rising infection rate, the chemotherapy-induced myelosuppression treatment market saw a moderately lower demand.
However, the rising number of patients with lung cancer and other cancers that are more susceptible to infection as a result of the virus has given the industry a boost. The growing demand for a variety of treatment options to reduce the risk of anaemia or thrombocytopenia is expected to drive market growth over the coming years.
Ley manufacturers of chemotherapy-induced myelosuppression treatment devices are focusing on increasing their geographical footprint as well as launching new products to increase their revenue generation in the chemotherapy-induced myelosuppression treatment market.
For instance,
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | Value in US$ Million |
| Key Regions Covered |
|
| Key Countries Covered |
|
| Key Market Segments Covered |
|
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global chemotherapy-induced myelosuppression treatment market is valued at US$ 8.06 Bn in 2022, and is projected to reach US$ 9.78 Bn by 2028.
Novartis AG, Amgen Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Myelo Therapeutics GmbH are key players in the market.
Increasing prevalence of cancer across the globe coupled with rising aging population and growing preference for chemotherapy are factors driving market growth.
Neutropenia accounts for 61.6% share of the chemotherapy-induced myelosuppression treatment market.
The market is estimated to exhibit a CAGR of 3.3% during the forecast period (2022-2028).
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
2.3. Inclusion and Exclusions
3. Chemotherapy-Induced Myelosuppression Treatment Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Chemotherapy-Induced Myelosuppression Treatment Market Evolution
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
5. Macroeconomic Assumptions
6. Global Economic Outlook
6.1. Gross Domestic Product by Region & Country, 2016 - 2021
7. Key Inclusions
7.1. Key Regulations
7.2. Pipeline Assessment
7.3. Patient Treatment Regimen/Patient Journey
8. Global Market Analysis 2013-2021 and Forecast 2022-2028
8.1. Market Value Share Analysis
8.2. Y-o-Y Growth Analysis
8.3. Absolute $ Opportunity
9. North America Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021
9.2.1. U.S.
9.2.2. Canada
9.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
9.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021
9.4.1. Growth Factors
9.4.1.1. Granulocyte Colony-Stimulating Factor
9.4.1.2. Thrombopoietin Receptor Agonists
9.4.2. Erythropoietin-stimulating Agents
9.4.3. Thrombopoietic Agents
9.4.4. Iron supplementation
9.4.5. Others
9.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
9.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
9.6.1. Oral
9.6.2. Injectable
9.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
9.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021
9.8.1. Anemia
9.8.2. Neutropenia
9.8.3. Thrombocytopenia
9.9. Market Size (US$ Mn) Forecast By Indication, 2022-2028
9.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
9.10.1. Hospital Pharmacies
9.10.2. Retail Pharmacies
9.10.3. Drug Stores
9.10.4. Online Pharmacies
9.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
9.12. Market Attractiveness Analysis
9.12.1. By Country
9.12.2. By Drug Class
9.12.3. By Route of Administration
9.12.4. By Indication
9.12.5. By Distribution Channel
9.13. Drivers and Restraints - Impact Analysis
10. Latin America Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028
10.1. Introduction
10.2. Historical Market Size (US$ Mn) By Country, 2013-2021
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Argentina
10.2.4. Rest of Latin America
10.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
10.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021
10.4.1. Growth Factors
10.4.1.1. Granulocyte Colony-Stimulating Factor
10.4.1.2. Thrombopoietin Receptor Agonists
10.4.2. Erythropoietin-stimulating Agents
10.4.3. Thrombopoietic Agents
10.4.4. Iron supplementation
10.4.5. Others
10.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
10.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
10.6.1. Oral
10.6.2. Injectable
10.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
10.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021
10.8.1. Anemia
10.8.2. Neutropenia
10.8.3. Thrombocytopenia
10.9. Market Size (US$ Mn) Forecast By Indication, 2022-2028
10.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacies
10.10.3. Drug Stores
10.10.4. Online Pharmacies
10.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
10.12. Market Attractiveness Analysis
10.12.1. By Country
10.12.2. By Drug Class
10.12.3. By Route of Administration
10.12.4. By Indication
10.12.5. By Distribution Channel
10.13. Drivers and Restraints - Impact Analysis
11. Western Europe Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028
11.1. Introduction
11.2. Historical Market Size (US$ Mn) By Country, 2013-2021
11.2.1. Germany
11.2.2. France
11.2.3. U.K.
11.2.4. Spain
11.2.5. Italy
11.2.6. Rest of Western Europe
11.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
11.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021
11.4.1. Growth Factors
11.4.1.1. Granulocyte Colony-Stimulating Factor
11.4.1.2. Thrombopoietin Receptor Agonists
11.4.2. Erythropoietin-stimulating Agents
11.4.3. Thrombopoietic Agents
11.4.4. Iron supplementation
11.4.5. Others
11.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
11.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
11.6.1. Oral
11.6.2. Injectable
11.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
11.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021
11.8.1. Anemia
11.8.2. Neutropenia
11.8.3. Thrombocytopenia
11.9. Market Size (US$ Mn) Forecast By Indication, 2022-2028
11.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Drug Stores
11.10.4. Online Pharmacies
11.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
11.12. Market Attractiveness Analysis
11.12.1. By Country
11.12.2. By Drug Class
11.12.3. By Route of Administration
11.12.4. By Indication
11.12.5. By Distribution Channel
11.13. Drivers and Restraints - Impact Analysis
12. Eastern Europe Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028
12.1. Introduction
12.2. Historical Market Size (US$ Mn) By Country, 2013-2021
12.2.1. Russia
12.2.2. Poland
12.2.3. Rest of Eastern Europe
12.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
12.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021
12.4.1. Growth Factors
12.4.1.1. Granulocyte Colony-Stimulating Factor
12.4.1.2. Thrombopoietin Receptor Agonists
12.4.2. Erythropoietin-stimulating Agents
12.4.3. Thrombopoietic Agents
12.4.4. Iron supplementation
12.4.5. Others
12.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
12.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
12.6.1. Oral
12.6.2. Injectable
12.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
12.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021
12.8.1. Anemia
12.8.2. Neutropenia
12.8.3. Thrombocytopenia
12.9. Market Size (US$ Mn) Forecast By Indication, 2022-2028
12.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Drug Stores
12.10.4. Online Pharmacies
12.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
12.12. Market Attractiveness Analysis
12.12.1. By Country
12.12.2. By Drug Class
12.12.3. By Route of Administration
12.12.4. By Indication
12.12.5. By Distribution Channel
12.13. Drivers and Restraints - Impact Analysis
13. Asia Pacific excluding China (APEC) Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028
13.1. Introduction
13.2. Historical Market Size (US$ Mn) By Country, 2013-2021
13.2.1. China
13.2.2. India
13.2.3. Australia and New Zealand
13.2.4. ASEAN
13.2.5. Rest of APAC
13.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
13.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021
13.4.1. Growth Factors
13.4.1.1. Granulocyte Colony-Stimulating Factor
13.4.1.2. Thrombopoietin Receptor Agonists
13.4.2. Erythropoietin-stimulating Agents
13.4.3. Thrombopoietic Agents
13.4.4. Iron supplementation
13.4.5. Others
13.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
13.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
13.6.1. Oral
13.6.2. Injectable
13.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
13.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021
13.8.1. Anemia
13.8.2. Neutropenia
13.8.3. Thrombocytopenia
13.9. Market Size (US$ Mn) Forecast By Indication, 2022-2028
13.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Drug Stores
13.10.4. Online Pharmacies
13.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
13.12. Market Attractiveness Analysis
13.12.1. By Country
13.12.2. By Drug Class
13.12.3. By Route of Administration
13.12.4. By Indication
13.12.5. By Distribution Channel
13.13. Drivers and Restraints - Impact Analysis
14. Japan Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021
14.2.1. Growth Factors
14.2.1.1. Granulocyte Colony-Stimulating Factor
14.2.1.2. Thrombopoietin Receptor Agonists
14.2.2. Erythropoietin-stimulating Agents
14.2.3. Thrombopoietic Agents
14.2.4. Iron supplementation
14.2.5. Others
14.3. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
14.4. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
14.4.1. Oral
14.4.2. Injectable
14.5. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
14.6. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021
14.6.1. Anemia
14.6.2. Neutropenia
14.6.3. Thrombocytopenia
14.7. Market Size (US$ Mn) Forecast By Indication, 2022-2028
14.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Drug Stores
14.8.4. Online Pharmacies
14.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
14.10. Market Attractiveness Analysis
14.10.1. By Drug Class
14.10.2. By Route of Administration
14.10.3. By Indication
14.10.4. By Distribution Channel
14.11. Drivers and Restraints - Impact Analysis
15. MEA Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028
15.1. Introduction
15.2. Historical Market Size (US$ Mn) By Country, 2013-2021
15.2.1. GCC Countries
15.2.2. South Africa
15.2.3. Rest of MEA
15.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
15.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021
15.4.1. Growth Factors
15.4.1.1. Granulocyte Colony-Stimulating Factor
15.4.1.2. Thrombopoietin Receptor Agonists
15.4.2. Erythropoietin-stimulating Agents
15.4.3. Thrombopoietic Agents
15.4.4. Iron supplementation
15.4.5. Others
15.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
15.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
15.6.1. Oral
15.6.2. Injectable
15.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
15.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021
15.8.1. Anemia
15.8.2. Neutropenia
15.8.3. Thrombocytopenia
15.9. Market Size (US$ Mn) Forecast By Indication, 2022-2028
15.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
15.10.1. Hospital Pharmacies
15.10.2. Retail Pharmacies
15.10.3. Drug Stores
15.10.4. Online Pharmacies
15.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
15.12. Market Attractiveness Analysis
15.12.1. By Country
15.12.2. By Drug Class
15.12.3. By Route of Administration
15.12.4. By Indication
15.12.5. By Distribution Channel
15.13. Drivers and Restraints - Impact Analysis
16. Forecast Factors: Relevance and Impact
17. Forecast Assumptions
18. Competition Analysis
18.1. Competition Dashboard
18.2. Market Structure Analysis
18.3. Company Deep Dive
18.3.1. Amgen Inc.
18.3.1.1. Overview
18.3.1.2. Product and Application Portfolio
18.3.1.3. Production Footprint
18.3.1.4. Sales Footprint
18.3.1.5. Channel Footprint
18.3.1.6. Strategy
18.3.1.6.1. Marketing Strategy
18.3.1.6.2. Product Strategy
18.3.1.6.3. Channel Strategy
18.3.2. Novartis AG
18.3.3. Teva Pharmaceutical Industries Ltd
18.3.4. Mylan N.V.
18.3.5. Pfizer Inc.
18.3.6. Janssen Global Services, LLC (Johnson & Johnson)
18.3.7. Partner Therapeutics, Inc.
18.3.8. Mission Pharmacal Company
18.3.9. Myelo Therapeutics GmbH
18.3.10. Dova Pharmaceutical
19. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Region
19.1. Introduction / Key Findings
19.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013-2021
19.2.1. North America
19.2.2. Latin America
19.2.3. Western Europe
19.2.4. Eastern Europe
19.2.5. Asia Pacific excluding Japan
19.2.6. Japan
19.2.7. Middle East and Africa
19.2.8. Market Size (US$ Mn) Forecast By Region, 2022-2028
19.2.9. Market Attractiveness Analysis By Region
20. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
20.1. Introduction
20.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021
20.2.1. Growth Factors
20.2.1.1. Granulocyte Colony-Stimulating Factor
20.2.1.2. Thrombopoietin Receptor Agonists
20.2.2. Erythropoietin-stimulating Agents
20.2.3. Thrombopoietic Agents
20.2.4. Iron supplementation
20.2.5. Others
20.3. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
20.4. Market Attractiveness Analysis By Drug Class
21. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration
21.1. Introduction
21.2. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021
21.2.1. Oral
21.2.2. Injectable
21.3. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028
21.4. Market Attractiveness Analysis By Route of Administration
22. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Indication
22.1. Introduction
22.2. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021
22.2.1. Anemia
22.2.2. Neutropenia
22.2.3. Thrombocytopenia
22.3. Market Size (US$ Mn) Forecast By Indication, 2022-2028
22.4. Market Attractiveness Analysis By Indication
23. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
23.1. Introduction
23.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
23.2.1. Hospital Pharmacies
23.2.2. Retail Pharmacies
23.2.3. Drug Stores
23.2.4. Online Pharmacies
23.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028
23.4. Market Attractiveness Analysis By Distribution Channel
24. Research Methodology
Explore Healthcare Insights
View Reports
Chemotherapy-Induced Myelosuppression Treatment Market
